Purpose: To examine the relationship between microaneurysm turnover (formation rate), using a new semi-automatic method (MA-Tracker) based on color fundus photographs, and diabetic retinopathy (DR) progression to clinically significant macular edema (CSME). Methods: In total, 113 patients/eyes with nonproliferative DR (NPDR) were followed up every 6 months for 2 years as controls of the DR clinical trials, and by conventional general and ophthalmological care for the next 8 years (over a total of 10 years’ follow-up). Microaneurysm turnover for the 2 first years was computed using the MA-Tracker. Results: The 17 patients that developed CSME over the 10 years of follow-up presented a microaneurysm formation rate of 9.2 ± 18.2 microaneurysms/year (mean ± SD) during the first 2 years, which was statistically higher than the eyes that did not develop CSME (0.5 ± 1.2 microaneurysms/year, p < 0.001). These 17 patients also presented higher HbA1C levels at baseline (8.5 ± 1.2%) compared to the patients who did not develop CSME (7.3 ± 1.2%, p = 0.001). Conclusions: A high microaneurysm formation rate on color fundus photographs appears to be a good biomarker for DR progression to CSME in type 2 diabetic patients with NPDR.

Keywords:
Microaneurysm count, Microaneurysm turnover, Microaneurysm formation rate, Microaneurysm disappearance rate, Diabetic retinopathy, Image co-registration, Color fundus photography
1.
Cunha-Vaz J: Characterization and relevance of different diabetic retinopathy phenotypes. Dev Ophthalmol 2007;39:13–30.
2.
Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR: Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia 1999;42:1107–1112.
3.
Hove MN, Kristensen JK, Lauritzen T, Bek T: The relationships between risk factors and the distribution of retinopathy lesions in type 2 diabetes. Acta Ophthalmol Scand 2006;84:619–623.
4.
Klein R, Klein B, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16.
5.
Hellstedt T, Immonen I: Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Br J Ophthalmol 1996;80:135–139.
6.
Kohner EM: Microvascular disease: what does the UKPDS tell us about diabetic retinopathy? Diabet Med 2008;25(suppl 2):20–24.
7.
Vander JM: Diabetic retinopathy; in Ho AC, Brown GC, McNamara A, Recchia FM, Regillio CD, Vander JF (eds): Retina: Color Atlas and Synopsis of Clinical Ophthalmology. Madrid, McGraw-Hill, 2003, pp 54–75.
8.
Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report number 2. Ophthalmology 1987;94:761–774.
9.
Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:767–785.
10.
Fleiss JL: Design and Analysis of Clinical Experiments. New York, John Wiley & Sons, 1986.
11.
Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174.
12.
Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(suppl):823–833.
13.
Lobo C, Bernardes R, Figueira JP, de Abreu JR, Cunha-Vaz JG: Three-year follow-up of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy. Arch Ophthalmol 2004;122:211–217.
14.
Csaky KG, Richman EA, Ferris FL: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008;49:479–489.
15.
Sharp PF, Olson J, Strachan F, Hipwell J, Ludbrook A, O’Donnell M, Wallace S, Goatman K, Grant A, Waugh N, McHardy K, Forrester JV: The value of digital imaging in diabetic retinopathy. Health Technol Assess 2003;7:1–119.
16.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.